hand-foot syndrome

hand-foot syndrome

a painful desquamative syndrome associated with 5-fluorouracil, especially if given in a continuous administration and with cytarabine.

hand-foot syndrome

Sickle cell dactylitis Hematology A 'crisis' in sickle cell anemia caused by sludging of RBCs in vessels and characterized by symmetric infarction of the small bones of the hand and foot, periosteal neoosteogenesis, pain and swelling that may occur as early as age 18 months, often resolving spontaneously within 1-4 wks. See Sickle cell anemia.
References in periodicals archive ?
Diffuse hyperpigmentation, Xerosis and Hand-foot syndrome, developed in 4 patients each.
Multikinase inhibitors, a common cause of hand-foot syndrome (HFS), are also associated with facial erythema, subungual splinter hemorrhages, and other skin changes, he added.
This side effect is known variously as hand-foot syndrome, palmar-plantar erythrodysesthesia (PPE) or hand-to-foot syndrome.
The most common grade 3/4 cediranib related toxicities on the original study were hypertension (36%), fatigue (30%), hand-foot syndrome (16%), and diarrhea (11%).
3) TEC includes Burgdorf's Reaction, erythrodysesthesia, acral erythema, toxic acral erythema, eccrine squamous syringometaplasia, epidermal dysmaturation, epidermal dystrophy, hand-foot syndrome, palmar-plantar erythema, palmarplantar dysesthesia, and neutrophilic eccrine hidradenitis.
Sunitinib; tyrosine kinase inhibitor; renal cell carcinoma; hand-foot syndrome.
In addition, infusion-related hypotension and hand-foot syndrome are new adverse events seen with the use of such liposomal formulations.
Sickle cell dactylitis, or hand-foot syndrome, is caused by localized bone marrow infarction of the carpal and tarsal bones and phalanges.
The most common adverse events associated with dabrafenib were hyperkeratosis, headache, fever, joint pain, noncancerous skin tumors, alopecia, and hand-foot syndrome.
In the Phase II randomized discontinuation trial, the most common Grade 3 or 4 adverse events that participants experienced included fatigue, hand-foot syndrome, hypertension, decreased appetite, nausea, and vomiting.
20 April 2011 - Spanish biopharmaceutical company Advancell has announced the initiation of a clinical Phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.
Cutaneous reactions: A number of oral agents are highly linked to reactions such as skin rash and hand-foot syndrome.